Among people with inflammatory rheumatic diseases and SARS-CoV-2 infection, having a connective tissue disease, but not inflammatory arthritis, is associated with an increased risk for severe COVID-19, Spanish researchers report.
Spotlight on: Repurposing rheumatology drugs for COVID-19
Findings from a systematic review and meta-analysis suggest that hydroxychloroquine is not associated with benefits or harms in terms of COVID-19 mortality, and more studies are needed to establish whether other rheumatology drugs could be used to treat the disease.
Spotlight on: Repurposing rheumatology drugs for COVID-19
Add-on treatment with an IL-6 receptor inhibitor warrants further investigation for patients with severe COVID-19 pneumonia and systemic hyperinflammation, suggest preliminary findings from two Italian observational studies published in the Annals of the Rheumatic Diseases.
Guidance for rheumatologists
Guidance and expert opinion on rheumatology practice during the COVID-19 pandemic
